Microba Life Sciences Limited (AU:MAP)
ASX:MAP
MAP Stock Chart & Stats
AU$0.08
>-AU$0.01(-1.89%)
At close: 4:00 PM EST
AU$0.08
>-AU$0.01(-1.89%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.23
Previous CloseN/A
Volume476.46K
Average Volume (3M)469.77K
Market Cap
AU$43.24M
Enterprise ValueAU$28.53M
Total Cash (Recent Filing)AU$11.27M
Total Debt (Recent Filing)AU$3.31M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding608,963,000
10 Day Avg. Volume548,444
30 Day Avg. Volume469,774
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.17
Price to Sales (P/S)2.43
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.21Price Target Upside162.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$18.83M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsMicroba's business model combines per-test consumer and clinician sales with fee-for-service B2B lab and analytics work and collaboration contracts. This multi-channel revenue base supports more durable demand, spreads commercial risk across end-markets, and enables step-ups in contracted R&D revenue over time.
Proprietary Sequencing & Bioinformatics PlatformThe company's sequencing, analytics and dataset capabilities are a structural competitive asset: they create technical barriers and reusable data that support differentiated clinical insights and service offerings. Such platform and data moats favor repeat B2B engagements and long-term licensing or study services.
Low Leverage With Positive Free Cash Flow GrowthA low debt load reduces refinancing risk and gives strategic optionality, while modest free cash flow growth signals improving cash generation capacity. Collectively these factors provide the company with greater financial flexibility to fund R&D, support commercialization, or withstand cyclical pressures without immediate reliance on dilutive financing.
Bears Say
Declining Revenue TrendSustained revenue declines materially weaken scale economics and erode the base needed to absorb fixed lab and R&D costs. Over several months this reduces reinvestment capacity, increases per-unit costs, and heightens the need for commercial turnaround or new contract wins to restore sustainable top-line growth.
Persistent Negative MarginsOperating losses driven by high operating expenses mean the business does not yet convert gross profit into operating profitability. Persistently negative margins constrain retained earnings and limit ability to self-fund expansion or absorb regulatory or pricing pressures, raising reliance on external capital for growth.
Negative Operating Cash Flow And Negative ROENegative operating cash flow shows core operations currently consume cash, while negative ROE indicates capital is not generating shareholder returns. Over months this cash burn trajectory can force fundraising, dilute shareholders or curtail strategic programs if operating performance does not improve.
Microba Life Sciences Limited News
MAP FAQ
What was Microba Life Sciences Limited’s price range in the past 12 months?
Microba Life Sciences Limited lowest share price was AU$0.07 and its highest was AU$0.23 in the past 12 months.
What is Microba Life Sciences Limited’s market cap?
Microba Life Sciences Limited’s market cap is AU$43.24M.
When is Microba Life Sciences Limited’s upcoming earnings report date?
Microba Life Sciences Limited’s upcoming earnings report date is Sep 02, 2026 which is in 142 days.
How were Microba Life Sciences Limited’s earnings last quarter?
Microba Life Sciences Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.018 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.008.
Is Microba Life Sciences Limited overvalued?
According to Wall Street analysts Microba Life Sciences Limited’s price is currently Undervalued.
Does Microba Life Sciences Limited pay dividends?
Microba Life Sciences Limited does not currently pay dividends.
What is Microba Life Sciences Limited’s EPS estimate?
Microba Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microba Life Sciences Limited have?
Microba Life Sciences Limited has 608,963,000 shares outstanding.
What happened to Microba Life Sciences Limited’s price movement after its last earnings report?
Microba Life Sciences Limited reported an EPS of -AU$0.018 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went up 1.176%.
Which hedge fund is a major shareholder of Microba Life Sciences Limited?
Currently, no hedge funds are holding shares in AU:MAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Microba Life Sciences Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.21 (162.50% Upside)
AU$0.21 (162.50% Upside)
Blogger Sentiment
Bullish
AU:MAP Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.76%
12-Months-Change
Fundamentals
Return on Equity
-63.04%
Trailing 12-Months
Asset Growth
-14.63%
Trailing 12-Months
Company Description
Microba Life Sciences Limited
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases. The company was incorporated in 2017 and is based in Brisbane, Australia.
MAP Stock 12 Month Forecast
Average Price Target
AU$0.21
▲(162.50% Upside)
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Options Prices
Currently, No data available
---